MarginsXMarginsX
Home › Markets › Health Care › TYRA

Tyra Biosciences Inc. (TYRA)

TYRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$19.74
-1.42% on the day
Market cap
$1.4B
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerTYRA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001863127
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
45.8 months
$456.0M cash at September 30, 2026
Share count, 1 year
+29.4%
2025-10-31 to 2026-11-06 · +60.4% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$10.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$456.0M cash; operating cash flow -$29.9M a quarter.Report 2026-09-30
Shares outstanding69,082,747 (2026-11-06); 53,372,098 a year earlier; 43,058,747 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2026-09-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $20K, sold $10.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$51.1M-$32.2M$456.0MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$45.6M-$31.1M$73.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$39.3M-$32.6M$85.0MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$33.8M-$23.6M$77.4MNo debt tagsNeeds four quarters10-K 2026-03-02
Q3 2025
2025-09-30
Not filed-$29.9M-$22.4M$62.0MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$28.1M-$23.7M$98.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$28.1M-$25.5M$100.7MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$25.6M-$19.6M$92.0MNo debt tagsNeeds four quarters10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-15
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 428 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.3%
1 month+7.9%
3 months-20.0%
Year to date-23.8%
1 year+28.4%
From 52-week high-49.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
URGNUroGen Pharma Ltd.$28.10+7.33%$1.4B
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B
DMRADamora Therapeutics Inc.$22.50+4.14%$1.4B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier